Vanguard Capital Management
ANAB icon

Vanguard Capital Management’s AnaptysBio ANAB Stock Holding History

Vanguard Capital Management’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$61.2M Buy
906,233
+53,082
+6% +$3.22M ﹤0.01% 1825
2026
Q1 		$47.3M Buy
+853,151
New +$45.9M ﹤0.01% 1883

Other funds holding ANAB

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management's ANAB Position: Q2 2026 in Review

Vanguard Capital Management increased its AnaptysBio (ANAB) stake by 6.2% in Q2 2026, buying an estimated $3.22M and bringing the position to 906,233 shares worth $61.2M. The position accounts for ﹤0.01% of the portfolio, ranked #1825.

Vanguard Capital Management first reported a position in ANAB in Q1 2026 and has held it in 2 quarters since. 212 funds tracked by Wall St. Rank hold ANAB as of Q2 2026.

  • Vanguard Capital Management held 906,233 shares of AnaptysBio worth $61.2M as of Q2 2026.
  • Vanguard Capital Management bought 53,082 AnaptysBio shares in Q2 2026, an estimated $3.22M.
  • AnaptysBio made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #1825 holding.
  • Vanguard Capital Management first reported a position in AnaptysBio in Q1 2026 and has held it in 2 quarters since.
  • 212 funds tracked by Wall St. Rank held AnaptysBio as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.